| 000 | 01117 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250516113837.0 | ||
| 264 | 0 | _c20121009 | |
| 008 | 201210s 0 0 eng d | ||
| 022 | _a1538-3598 | ||
| 024 | 7 |
_a10.1001/2012.jama.11661 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKiechl, Stefan | |
| 245 | 0 | 0 |
_aBleeding risk with ischemic stroke therapy. _h[electronic resource] |
| 260 |
_bJAMA _cOct 2012 |
||
| 300 |
_a1318; author reply 1319-20 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 |
_aAnticoagulants _xadverse effects |
| 650 | 0 | 4 |
_aBrain Ischemia _xepidemiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFibrinolytic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aStroke _xdrug therapy |
| 650 | 0 | 4 |
_aTissue Plasminogen Activator _xadministration & dosage |
| 650 | 0 | 4 |
_aWarfarin _xadverse effects |
| 700 | 1 | _aKnoflach, Michael | |
| 700 | 1 | _aWilleit, Johann | |
| 773 | 0 |
_tJAMA _gvol. 308 _gno. 13 _gp. 1318; author reply 1319-20 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1001/2012.jama.11661 _zAvailable from publisher's website |
| 999 |
_c22154678 _d22154678 |
||